Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals Ltd |
| 1 |
| May 11, 2022 |
| clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | withdrawn | Phase 1 | 0 | Jordan KharofaOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03745690 | Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT03231475 | Phase I Study of SPH1188-11 in NSCLC(SPH1188-11) | withdrawn | Phase 1 | 0 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04585724 | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 0 | Oct 18, 2021 | clinicaltrials |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | withdrawn | Phase 1 / Phase 2 | 0 | NextCure, Inc.INDUSTRY | 0 | Aug 18, 2021 | clinicaltrials |
| NCT03245177 | Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)(PARIS) | withdrawn | Phase 1 | 0 | Prof Corinne Faivre-FinnOTHER | 0 | Jul 28, 2021 | clinicaltrials |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma(PANC-001) | withdrawn | Phase 1 | 0 | Roger Williams Medical CenterOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04205071 | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer | withdrawn | Phase 1 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 19, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Nov 3, 2020 | clinicaltrials |
| NCT04315155 | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation(BENEFIT) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 0 | Oct 28, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | withdrawn | Phase 1 | 0 | NanOlogy, LLCINDUSTRY | 0 | Aug 4, 2020 | clinicaltrials |
| NCT02451865 | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | withdrawn | Phase 1 | 0 | University of MinnesotaOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | May 20, 2020 | clinicaltrials |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516 | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 0 | Mar 18, 2020 | clinicaltrials |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin(iTRAP) | withdrawn | Phase 1 | 0 | Queen Mary University of LondonOTHER | 0 | Feb 25, 2020 | clinicaltrials |
| NCT03110445 | Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus(rVV-740CTA) | withdrawn | Phase 1 | 0 | University Hospital, Basel, SwitzerlandOTHER | 0 | Feb 7, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2022source: clinicaltrials